TransCode Advances Colorectal Cancer Drug to Phase 2

TransCode Therapeutics, a public biotech company, announced its lead drug TTXMC138 for colorectal cancer has advanced to Phase 2 trials. The drug targets microRNA-10b, a key regulator in metastatic cancer. Phase 1 results showed safety and some efficacy, with 71% of patients experiencing stable disease. The company has raised $100M with no long-term debt. Phase 2 trials focus on colorectal cancer, a high-mortality disease with unmet medical needs.

Original reporting
Published Nov 16, 2026, 4:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 4:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
TransCode Advances Colorectal Cancer Drug to Phase 2 — source image
Decision brief

The 30-second read

Low
01

Why it matters

The article is a forward-looking presentation describing the rationale for targeting microRNA-10b and summarizing prior Phase 0 and Phase 1a safety/tolerability and disease stabilization signals, then stating the program is now in Phase 2 for colorectal cancer with an MRD (ctDNA) approach.

02

Market read

For traders, the actionable takeaway is limited because the excerpt does not provide a new, time-stamped clinical datapoint, regulatory decision, or financing event; it mainly reiterates prior Phase 0/1a results and states Phase 2 is underway.

03

What to watch

Key commercial and risk items are missing in the text: trial design details for Phase 2 (primary endpoint, comparator, sample size), manufacturing/delivery platform validation, and whether ctDNA MRD regulatory pathway is expected to be accepted for approval.

Relevance 4/10Novelty 4/10Timing: conference/recorded presentation context, no explicit new filing or FDA decision date in text

Background

TransCode Therapeutics is described as a small biotech developing RNA therapeutics using its TTX delivery platform, with a lead program TTXMC138 targeting colorectal cancer in Phase 2.

Market effects

Highlights continued investor interest in RNA therapeutics and ctDNA MRD-guided oncology strategies, but no cross-company read-across is provided.

No clear regional market linkage beyond general biotech sentiment.

Oncology trial progress is globally relevant, but the article provides no multinational regulatory or market access milestones.

Counterpoint

Phase 2 advancement is promising, but the excerpt does not include Phase 2 enrollment status, endpoints, or any new efficacy datapoint beyond earlier Phase 1a stabilization.

Key entities

  • TransCode Therapeutics

    Subject of the article; lead candidate TTXMC138 is described as advancing in colorectal cancer to Phase 2.

  • TTXMC138

    Lead compound targeting microRNA-10b, described as in Phase 2 for colorectal cancer.

  • TTX delivery platform

    Proprietary delivery platform described as enabling tumor-agnostic RNA delivery.

  • microRNA-10b (miR10b)

    Targeted master regulator in metastatic cancer, described as involved in invasion, metastasis, immune evasion, and chemoresistance.

  • ctDNA

    Used as the MRD tool to identify high-risk patients post-surgery/chemotherapy.

Related articles

$RNAZMedAI 8/10

TransCode presents phase 1a trial data for cancer therapy

TransCode Therapeutics (RNAZ) presented Phase 1a trial data for TTX-MC138 at ESMO Congress 2026. The study met safety endpoints, showed dose-dependent exposure, and indicated disease stabilization and extended progression-free intervals in some patients. TTX-MC138 is being evaluated in a Phase 2a trial under the PRE-I-SPY program.

$NTRAMed

Natera partners with TransCode for cancer trial enrollment

Natera Inc. (NTRA) and TransCode Therapeutics Inc. (RNAZ) announced a collaboration to enroll patients in a colorectal cancer clinical trial using Natera's Signatera test to identify eligible patients. The trial targets patients at risk of recurrence but with no approved therapies. TransCode's TTX-MC138 aims to inhibit a biomarker linked to metastatic cancers. The trial is part of the PRE-I-SPY program and is registered at clinicaltrials.gov.

$RNAZMedAI 8/10

TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up

Transcode Therapeutics, Inc. (RNAZ) filed an SEC Form 8-K — Other Events. Exhibit 99.1 TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up Updated clinical data reinforces evidence of antitumor activity in heavily pretreated patients with advanced solid tumors · I

$VRAXMed

Top Biotech Gainers: VRAX Jumps 100% After Fosun Deal, FBRX Soars On Vitiligo Data, TRAX On Watch

Biotech stocks rose on company-specific catalysts. Virax Biolabs (VRAX) jumped over 100% after signing an exclusive multi-country supply agreement with Fosun Diagnostics for ImmuneSelect. Forte Biosciences (FBRX) gained about 78% on positive Phase 1b vitiligo data for FB102. First Tracks (TRAX) rose ~56% without news. TransCode (RNAZ) and Connect Biopharma (CNTB) also climbed; Sanuwave (SNWV) fell guidance and expects Q2 revenue of $8.5m to $9.5m.

$PBLSMed

Top Biotech Gainers: PBLS Soars Over 50%, CLOV Rallies On Legal Win, RNAZ, TMCI On Watch

Biotech stocks rose on varied catalysts. Parabilis (PBLS) debuted on Nasdaq, up 58% to $31.60 after pricing a $20.00 IPO of 33.5M shares for ~$670M gross proceeds. Clover Health (CLOV) gained 14% to $4.89 after a court ruling upgraded its 2026 PPO Star Rating to 4.5 from 3.5. Myomo (MYO) rose 17% to $1.54; Shoulder Innovations (SI) up 17% to $17.89; GMRS up 13% to $13.18.